Fresenius Kabi has introduced its alternative of Takeda Oncology’s Velcade (bortezomib for injection). The Lake Zurich, Ill.-based company said that this addition to its oncology offerings is the first available alternative for intravenous use.
Fresenius Kabi’s product is available in a single-dose vial that contains 3.5 mg of lyophilized powder.
Shiseido is looking to blend the worlds of beauty, technology and dermatology with its latest announcement. The Tokyo-based company has revealed that its subsidiary, Shiseido Americas, has acquired all assets of Massachusetts-based startup, Olivo Labs.
Attendees of this year’s National Association of Chain Drug Stores Annual Meeting will get to hear from bestselling author and business consultant Jim Collins, the Arlington, Va.-based trade group announced Thursday.
Collins has written or co-authored six books that sold more than 10 million copies worldwide, including his bestseller Good to Great, which examines how good companies become great companies.